Mednet Logo
HomeHematologyQuestion

What factors besides disease progression would lead you to de-intensify or change MM therapy for a patient with ongoing response?

2
3 Answers
Mednet Member
Mednet Member
Medical Oncology · Massachusetts General Hospital

After initial therapy (which may or may not include an autologous stem cell transplant), patients are generally on continuous/maintenance therapy with e.g. lenalidomide as the most common regimen. Most patients do well on this as maintenance. However, loose stools are probably the most common compla...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center

Completely agree with Dr. @Dr. First Last on all fronts. Assuming this question specifically pertains to lenalidomide maintenance, I'll also add:

1) If you're unsure whether your patient's symptoms are lenalidomide-related or not during maintenance, the difference between continuous lenalidomide (e....

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic

Alterations in therapy will be dictated by disease response as well as toxicity related to the therapy period. If the patient is not having a good disease response or if there is evidence of disease progression, one should consider changing the regimen completely with the introduction of new drugs i...

Register or Sign In to see full answer